ArticleScientific reports2025
Bioinformatics analysis reveals C5AR1's impact on thyroid cancer development via immune infiltration.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Thyroid cancer (THCA) remains a prevalent endocrine malignancy, with limited molecular markers for accurate diagnosis and targeted therapy. This study aimed to identify key biomarkers and therapeutic targets for THCA using integrative bioinformatics and experimental validation. We used differential gene expression analysis, gene enrichment analysis, protein-protein interaction (PPI) network construction, and machine learning algorithms to identify potential biomarkers. Receiver operating characteristic (ROC) curve analysis, immunohistochemical data from the Human Protein Atlas (HPA), quantitative real-time PCR (qPCR), and immune infiltration analysis were used for further validation. Additionally, ROC and multivariate Cox regression analyses were conducted to quantitatively evaluate the diagnostic and prognostic performance of candidate genes. Four candidate biomarkers (VEGFA, TYK2, NRP1, and C5AR1) were identified, but only C5AR1 showed statistical significance in ROC and prognostic analyses. Specifically, C5AR1 demonstrated a strong diagnostic value (AUC = 0.873, 95% CI: 0.822-0.924) and was significantly associated with poorer overall survival (hazard ratio [HR] = 2.41, 95% CI: 1.15-5.06, p = 0.021). Further qPCR and immune infiltration analyses confirmed that C5AR1 expression was associated with immune cell infiltration, potentially influencing THCA progression. This study identifies C5AR1 as a key biomarker in THCA, suggesting its role in immune-related tumor progression. These findings indicate statistical associations rather than causal mechanisms, highlighting the need for further experimental validation. The results provide a foundation for targeted immunotherapy strategies in THCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.